“You don't see value in identifying false or misleading information? I have some recent examples if you'd like me to specify.”
I do, and also do my best to refute misleading statements when I see them. You will also notice that I gladly accept convincing argument and learn from them.
I believe there is a lot of "unhelpful" and " patently false or misleading information " info on this board but I do not see it coming from those discussing the possible benefits of the drug.
One of the greatest deceptions is exaggerating trial recruitment timelines and readout far into the future based on historical U.S. data. This is inappropriate because the trials are not in the U.S. and the likelihood of provisional approval is high simply because there are no effective treatments for these diseases. Medical records and treatment protocols are highly fragmented in the U.S. and that makes it much more difficult to run trials here.
This is the same reason that approval in another country is likely to generate Asian conditional approval.
Those that say that any approval must wait till 2020 are giving misleading information, in my opinion.
It is also very misleading to say that Donepezil is a superior S1R receptor. 2-73 has given benefit for years, months is the most anyone can expect from Donepezil. There is a conflating of efficacy and chemical binding which is very deceptive.
Market Data 
Markets 
AI
